Jiankuan registers Phase 3 trial of proximod in rheumatoid arthritis
Jiankuan (Suzhou) Biotechnology Company Limited registered a Phase 3 trial of proximod for moderate-to-severe active rheumatoid arthritis. The study plans to enroll 590 participants and is expected to start on October 15, 2026.
Primary source
ClinicalTrials.gov registry record, October 2, 2026
A Study to Evaluate the Efficacy and Safety of Proximod in Patients With Rheumatoid Arthritis
Read the source: A Study to Evaluate the Efficacy and Safety of Proximod in Patients With Rheumatoid Arthritis clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation